T1D Fund

T1D Fund is a mission-driven venture investor focused exclusively on accelerating therapies, devices, and platform technologies that improve the lives of people with type 1 diabetes and ultimately move the field toward cures. The fund concentrates on pharma and therapeutics alongside medical devices and medtech, supporting science-led companies whose programs target the underlying biology of T1D, complications, or near-term clinical management. By orienting around a single disease area, the fund builds deep technical fluency in immunology, beta cell biology, closed-loop systems, and adjacent platforms relevant to T1D outcomes.

The firm is based in Boston and writes checks in the $1M to $5M range across Seed, Series A, Series B, and Series C rounds. Its multi-stage posture lets it support companies from early scientific validation through clinical development and commercial scale-up, often alongside traditional life sciences syndicates. The U.S. base puts it close to leading academic medical centers, the broader Boston biotech ecosystem, and the patient and clinical communities most engaged with T1D care.

T1D Fund engages founders and management teams whose programs are scientifically rigorous and have a credible line of sight to meaningful clinical impact for people with type 1 diabetes. The team values straightforward technical discussions, realistic development plans, and a clear framing of how a program fits into the broader T1D treatment landscape. Founders should expect a partner who brings disease-area conviction, connections into the T1D clinical and patient communities, and a willingness to support long development arcs when the underlying science warrants it.